Bristol Myers Squibb entered two separate research collaboration and licensing deals, one with San Francisco-based SyntheX and the second with London’s Autolus Therapeutics.
Early data from the Phase III TALAPRO-2 study showed Talzenna (talazoparib), Pfizer’s oral PARP inhibitor, met its primary endpoint in metastatic castration-resistant prostate cancer patients, the company announced Tuesday.
Life-threatening safety concerns prompted KalVista Pharmaceuticals to shut down a mid-stage clinical trial for hereditary angioedema, the swelling of skin in response to an allergic reaction, the company announced Tuesday.
U.S. President Joe Biden will announce new guidelines and grants to protect reproductive rights on Tuesday, and describe how abortion rights have been curtailed since the Supreme Court overturned the constitutional right to terminating pregnancies.
A public inquiry into Britain’s response to and handling of the COVID-19 pandemic got under way on Tuesday, with a promise it would get to the truth, and expose any wrongdoing or culpable conduct.
A World Health Organization spokesperson said on Tuesday it was setting up tents to treat cholera in Haiti and would also request the supply of oral vaccines against the disease, which has unexpectedly returned to a country paralyzed by a gang blockade.
The Centers for Disease Control and Prevention (CDC) said on Monday it had ended its COVID-19 country travel health notices as fewer countries reported enough data for accurate assessments.
Grifols appointed an executive chairman on Monday, as the Spanish pharmaceutical company strives to recover from a pandemic-related hit and a 49% drop in its shares so far this year.
The U.S. Supreme Court on Monday declined to hear a challenge by Missouri and nine other states – mostly Republican-led – to President Joe Biden’s COVID-19 vaccine mandate for workers in healthcare facilities that receive federal funds.
Through its Alexion subsidiary, AstraZeneca is acquiring Lexington, Mass.-based LogicBio Therapeutics in a deal worth $68 million. The deal bolsters AstraZeneca’s efforts in genomics and rare diseases.